Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Bird flu poses risk of pandemic worse than COVID, France's Institut Pasteur says - 2Artemis II live updates: NASA's moon mission breaks Apollo record for farthest distance humans have traveled from Earth
- 3NASA's Artemis 2 pilot Victor Glover listens to 'Whitey on the Moon' every Monday. This is why.
- 4New heart disease calculator predicts 30-year risk for young adults
- 5People can't get enough of this couple's Hallmark movie reviews. They don't know the painful backstory.
- Select Your Go-To Bluetooth Earphones
- Scientists dove hundreds of feet into the ocean and found creatures no human has ever seen. Our trash beat us there
- A definitive Handbook for Securities exchange Money management
- Polish law aimed at lowering petrol prices takes effect on Tuesday
- Factbox-Artemis II crew includes first woman, Black astronaut and Canadian ever flown to moon
- Surf Spot Mechanics: Bells Beach
- Is relief in sight? Flu season still brutal but cases are declining.
- Indian Health Service is digging out of decades-old construction backlog for medical buildings
- Figure out How to Augment the Advantages of a Web-based Degree
